Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Binzhou People's Hospital | OTHER |
| Tai'an People's Hospital | UNKNOWN |
| Linyi People's Hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Prucalopride based bowel cleansing regimen might be helpful to improve bowel cleansing quality before colonoscopy.
Colonoscopy is the standard approach for evaluating the colon currently. Thorough bowel cleansing is critical for adequate visualization of colonic mucosa during colonoscopy. Inadequate bowel cleansing results in adverse consequences for the examination, including lower adenoma detection rates, longer procedural time, lower cecal intubation rates, shorter intervals between examinations and an estimated 12-22% increase in overall colonoscopy cost.Unfortunately, despite advances in bowel preparation methods, up to one-third of all colonoscopies are reported to have an inadequate bowel preparation.
Prucalopride can accelerate colonic transit and has been demonstrated to be efficient in constipation.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Prucalopride group | Experimental | 2 mg Prucalopride plus 2 L Polyethylene Glycol regimen |
|
| Placebo group | Placebo Comparator | 2 mg Placebo plus 2 L Polyethylene Glycol regimen |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 2 mg Prucalopride plus 2 L Polyethylene Glycol regimen | Drug | Patients enrolled in the Prucalopride group will recieve 2 mg Linaclotide plus 2 L Polyethylene Glycol regimen before colonoscopy. |
| Measure | Description | Time Frame |
|---|---|---|
| Difference of scores rating by Boston Bowel Preparation Scale between 2 groups. | This is an established rating scale to evaluate the quality of bowel prep. The ratings will be compared between 2 groups. | 9 months |
| Measure | Description | Time Frame |
|---|---|---|
| Polyp detection rate between 2 groups. | 9 months | |
| rate of adverse events between 2 groups. | 9 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Li Yanqing, MD, PhD | Contact | 86-531-82169236 | liyanqing@sdu.edu.cn |
| Name | Affiliation | Role |
|---|---|---|
| Li Yanqing, MD, PhD | Qilu Hospital of Shandong University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Gastroenterology, Qilu Hospital, Shandong University | Jinan | Shandong | 250012 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
| 2 mg Placebo plus 2 L Polyethylene Glycol regimen | Drug | Patients enrolled in the Placebo group will recieve 2 mg Placebo plus 2 L Polyethylene Glycol regimen before colonoscopy. |
|
| ID | Term |
|---|---|
| C406662 | prucalopride |
Not provided
Not provided
Not provided